Allergy or hypersensitivity to components of the cobimetinib formulations
Previously identified allergy or hypersensitivity to components of the cabozantinib formulations
Previously identified allergy or hypersensitivity to components of the study treatment formulations
Previously identified hypersensitivity to components of the formulations used in this study
Known allergy or hypersensitivity to the components of the doxorubicin, cyclophosphamide, carboplatin, or paclitaxel formulations.
Known allergy or hypersensitivity to liposomal or pegylated G-CSF formulations.
History of severe hypersensitivity reactions to components of the cobimetinib, atezolizumab, or pembrolizumab formulations
Previously identified allergy or hypersensitivity to any component of the study treatment formulations
Previously identified allergy or hypersensitivity to components of the study treatment formulations
Has a previously identified allergy or hypersensitivity to components of the study treatment formulations
Known allergy or hypersensitivity to study drug formulations
Previously identified allergy or hypersensitivity to components of the study treatment formulations
Patients with a known allergy to any component of the study treatment formulations
Previously identified allergy or hypersensitivity to components of the study treatment formulations
Previously identified allergy or hypersensitivity to components of the study treatment formulations
Allergy or hypersensitivity to components of the cobimetinib formulations
Patient has a known allergy to any component of the study treatment formulations
Previously identified allergy or hypersensitivity to components of the study treatment formulations.
Allergy or hypersensitivity to components of the cobimetinib formulations
The patient has a previously-identified allergy or hypersensitivity to components of the study treatment formulations.
History of serious allergy or reaction to any component of RICE or RDHAP formulations that would prevent administration
